University of New Mexico

Running trials

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Psilocybin for Opioid Use Disorder (OUD)

  NCT06796062· Phase 2· NYU Langone Health· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

  NCT07290803· Sanofi· Source

• Recruiting

  Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

  NCT06795009· Phase 1· Washington University School of Medicine· Source

• Recruiting

  Opioid Adherence and Support Through Innovative Texting Strategies

  NCT07350148· University of New Mexico· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Recruiting

  Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

  NCT06837181· Jaeb Center for Health Research· Source

• Recruiting

  A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

  NCT06624644· Phase 2/3· Linnaeus Therapeutics, Inc.· Source

• Recruiting

  RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

  NCT07002034· Phase 2· Reunion Neuroscience Inc· Source

• Recruiting

  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  NCT06911632· Tempus AI· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Mindfulness Texting for Medication Adherence and Chronic Pain Management

  NCT07711795· University of New Mexico· Source

• Recruiting

  A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

  NCT06680830· Phase 2· Neuron23 Inc.· Source

• Recruiting

  Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

  NCT06585410· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

  NCT06712407· Phase 4· Asahi Kasei Therapeutics, AB· Source

• Recruiting

  Uterine Preservation Via Lifestyle Transformation

  NCT05903131· Phase 2· Washington University School of Medicine· Source

• Recruiting

  Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

  NCT06468202· Phase 4· Ohio State University· Source

• Recruiting

  DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

  NCT06445946· Phase 4· Ohio State University· Source

• Active, not recruiting

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

  NCT06372145· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

• Recruiting

  Effects of Multiple-Session Transcranial Direct Current Stimulation (tDCS) on Behavioral, Physiological, and Electrophysiological Measures With Adults With Autism Spectrum Disorder (ASD)

  NCT06495684· University of New Mexico· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

  NCT06241118· Phase 3· Sanofi· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06191744· Phase 3· Genmab· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Sanofi· Source

• Active, not recruiting

  Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

  NCT06141473· Phase 3· Sanofi· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· United Therapeutics· Source

• Active, not recruiting

  TeleHealth Resources for IndiVidualizEd Goals (THRIVE) in Alcohol Recovery Study

  NCT06074341· University of New Mexico· Source

• Recruiting

  Ketogenic Diet and Diabetes Demonstration Project

  NCT06115265· University of New Mexico· Source

• Active, not recruiting

  REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

  NCT05611918· Johns Hopkins University· Source

• Active, not recruiting

  Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial

  NCT05571917· University of New Mexico· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Genmab· Source

• Active, not recruiting

  A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

  NCT05506943· Phase 2/3· Compass Therapeutics· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Enrolling by invitation

  The Diabetes Prevention Program Outcomes Study AD/ADRD Project

  NCT05704309· Marinella Temprosa· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

• Active, not recruiting

  Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

  NCT05492578· Phase 2/3· Sanofi· Source

• Active, not recruiting

  A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

  NCT05451810· Phase 2· Genmab· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

  NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source

• Active, not recruiting

  Pain and Opioids: Integrated Treatment In Veterans

  NCT04648228· University of New Mexico· Source

• Active, not recruiting

  An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT04720157· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

  NCT04811560· Phase 1/2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Metformin in Alzheimer's Dementia Prevention

  NCT04098666· Phase 2/3· Columbia University· Source

• Active, not recruiting

  Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

  NCT04589845· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Parkinson's Foundation· Source

• Active, not recruiting

  Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

  NCT04524611· Phase 3· AbbVie· Source

• Enrolling by invitation

  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

  NCT03683186· Phase 3· United Therapeutics· Source

Showing 50 of 59.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease4 recruiting
• High blood pressure3 recruiting
• Multiple sclerosis3 recruiting
• Endometrial cancer2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Melanoma2 recruiting
• Obesity2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Type 2 diabetes2 recruiting
• Acute myeloid leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Autism1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Cystic fibrosis1 recruiting
• Gestational diabetes1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Duke University· Source

• Withdrawn

  Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD

  NCT06036511· Phase 1/2· University of New Mexico· Source

• Completed

  Making it Work Program for Systemic Sclerosis

  NCT06338722· University of New Mexico· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Terminated

  Feasibility of the ROADE Program

  NCT05911334· University of New Mexico· Source

• Completed

  A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

  NCT05798520· Phase 2· Biogen· Source

• Completed

  Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

  NCT05908240· University of Pennsylvania· Source

• Withdrawn

  Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

  NCT05890768· Phase 4· University of New Mexico· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee Osteoarthritis

  NCT05660772· Phase 3· Lipogems International spa· Source

• Completed

  Abbott i-STAT High Sensitivity Troponin I Study

  NCT05629572· Abbott Point of Care· Source

• Terminated

  STEM-PD Open Label Extension (OLE)

  NCT04799418· Scion NeuroStim· Source

• Completed

  RNS System NAUTILUS Study

  NCT05147571· NeuroPace· Source

• Completed

  STEM-Parkinson's Disease

  NCT04797611· Scion NeuroStim· Source

• Completed

  Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

  NCT05084638· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome

  NCT04717427· University of Illinois Chicago· Source

• Completed

  Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

  NCT05030415· Early phase 1· University of New Mexico· Source

• Completed

  A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

  NCT04809363· Phase 4· Takeda· Source

• Completed

  A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

  NCT04732221· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

  NCT04571619· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· AbbVie· Source

• Completed

  Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

  NCT04266197· Phase 2· Respira Therapeutics, Inc.· Source

• Completed

  Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Phase 3· Sanofi· Source

• Terminated

  PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

  NCT04517864· Phase 2· Pfizer· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Actelion· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

  NCT04410991· Phase 3· Sanofi· Source

• Completed

  Online Fatigue Intervention Program for People With Scleroderma

  NCT04401943· University of New Mexico· Source

• Completed

  Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

  NCT04166058· Phase 3· AbbVie· Source

• Completed

  Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

  NCT04026113· Phase 3· AbbVie· Source

• Recruiting

  A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

  NCT03887715· LivaNova· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Light Treatment Effectiveness (LITE) Study

  NCT03726489· University of Pennsylvania· Source

• Completed

  A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

  NCT03646604· Phase 1· AbbVie· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological Treatment for Alcohol Use Disorder

  NCT03842670· University of New Mexico· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

  NCT03607422· Phase 3· AbbVie· Source

• Completed

  Milrinone in Congenital Diaphragmatic Hernia

  NCT02951130· Phase 2· NICHD Neonatal Research Network· Source

• Completed

  Home-Based Kidney Care in Native American's of New Mexico (HBKC)

  NCT03179085· University of New Mexico· Source

• Completed

  Enhancing Prevention Pathways Toward Tribal Colorectal Health

  NCT02882620· University of New Mexico· Source

• Completed

  Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

  NCT02649790· Phase 1/2· Karyopharm Therapeutics Inc· Source

• Completed

  A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  NCT02163694· Phase 3· AbbVie· Source

• Completed

  Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

  NCT00936390· Phase 3· Radiation Therapy Oncology Group· Source